AD Testing Solutions

Cerebrospinal fluid (CSF) biomarkers, developed first by Fujirebio more than 25 years ago, have evolved over time from research to specialized diagnostic testing, and from use by early adopters to widespread routine testing today.

Assessing a patient’s CSF allows the detection of four proteins associated with Alzheimer’s disease: two forms of beta amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and hyperphosphorylated-Tau) proteins. In Alzheimer’s disease amyloid proteins (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) decline to abnormally low levels. The Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio may decline long before symptoms of the disease are manifested. Although still considered a research tool in the US, high tTotal Tau and phospho-Tau levels may also be observed in Alzheimer’s Disease.

There is an urgent clinical need for low-invasive, affordable techniques to assess the risk of Alzheimer's pathology in patients, that could help refer individuals to specialists for confirmatory testing. Plasma-based biomarkers for the two amyloid (Aβ1-42 and Aβ1-40) proteins and for the phospho-Tau protein are already available from Fujirebio for fully automated testing (for research use only). Research continues at the Fujirebio Neurology Center of Excellence, which has led, for example, to the release of new assays for two promising biomarkers, NPTX2 and sTREM2, both of which are available for research use.

Fujirebio contributes and collaborates globally within the clinical community and partner organizations to develop the neurodegeneration tools for the future.

Read more below or contact us today

Lumipulse^® Assays